Software company Induction Healthcare Group PLC (AIM: INHC) announced on Monday that it has been selected by the Health Service Executive (HSE) of the Republic of Ireland to provide its Attend Anywhere video platform as the national clinical video solution.
Starting 1 January 2025, the platform will be rolled out across Ireland's healthcare system, initially focusing on the acute sector.
The two-year contract, with the option for a third year, will provide a minimum of 1,500 licences, generating at least GBP0.3m in annual recurring revenue (ARR). HSE plans to scale usage to over 3,000 clinical users in the near term.
Attend Anywhere was chosen over generic solutions like Teams and Zoom due to its advanced waiting room functionality, enhanced security features and user-friendly interface for administrators.
Induction's software solutions, including Attend Anywhere, help healthcare providers deliver care both remotely and face-to-face, integrated with leading Electronic Medical Record platforms. The company's applications are trusted by national and regional healthcare systems across the UK and Ireland, serving hundreds of thousands of clinicians and millions of patients.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets